Literature DB >> 27856460

Architectural and functional heterogeneity of hematopoietic stem/progenitor cells in non-del(5q) myelodysplastic syndromes.

Virginie Chesnais1,2,3,4, Marie-Laure Arcangeli5, Caroline Delette1,2,3,4, Alice Rousseau1,2,3,4,6, Hélène Guermouche1,2,3,4,6, Carine Lefevre1,2,3,4, Sabrina Bondu1,2,3,4, M'boyba Diop7, Meyling Cheok8, Nicolas Chapuis1,2,3,4,6, Laurence Legros9, Sophie Raynaud10, Lise Willems11, Didier Bouscary1,2,3,4,11, Evelyne Lauret1,2,3,4, Olivier A Bernard7, Olivier Kosmider1,2,3,4,6, Françoise Pflumio5, Michaela Fontenay1,2,3,4,6.   

Abstract

Myelodysplastic syndromes (MDSs) are hematopoietic stem cell disorders in which recurrent mutations define clonal hematopoiesis. The origin of the phenotypic diversity of non-del(5q) MDS remains unclear. Here, we investigated the clonal architecture of the CD34+CD38- hematopoietic stem/progenitor cell (HSPC) compartment and interrogated dominant clones for MDS-initiating cells. We found that clones mainly accumulate mutations in a linear succession with retention of a dominant subclone. The clone detected in the long-term culture-initiating cell compartment that reconstitutes short-term human hematopoiesis in xenotransplantation models is usually the dominant clone, which gives rise to the myeloid and to a lesser extent to the lymphoid lineage. The pattern of mutations may differ between common myeloid progenitors (CMPs), granulomonocytic progenitors (GMPs), and megakaryocytic-erythroid progenitors (MEPs). Rare STAG2 mutations can amplify at the level of GMPs, from which it may drive the transformation to acute myeloid leukemia. We report that major truncating BCOR gene mutation affecting HSPC and CMP was beneath the threshold of detection in GMP or MEP. Consistently, BCOR knock-down (KD) in normal CD34+ progenitors modifies their granulocytic and erythroid differentiation. Clonal architecture of the HSPC compartment and mutations selected during differentiation contribute to the phenotypic heterogeneity of MDS. Defining the hierarchy of driver mutations provides insights into the process of transformation and may guide the search for novel therapeutic strategies.
© 2017 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27856460     DOI: 10.1182/blood-2016-03-707745

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  9 in total

1.  Erythrocytosis in the general population: clinical characteristics and association with clonal hematopoiesis.

Authors:  Hanneke J C M Wouters; René Mulder; Isabelle A van Zeventer; Jan Jacob Schuringa; Melanie M van der Klauw; Pim van der Harst; Arjan Diepstra; André B Mulder; Gerwin Huls
Journal:  Blood Adv       Date:  2020-12-22

2.  A variant erythroferrone disrupts iron homeostasis in SF3B1-mutated myelodysplastic syndrome.

Authors:  Sabrina Bondu; Anne-Sophie Alary; Carine Lefèvre; Alexandre Houy; Grace Jung; Thibaud Lefebvre; David Rombaut; Ismael Boussaid; Abderrahmane Bousta; François Guillonneau; Prunelle Perrier; Samar Alsafadi; Michel Wassef; Raphaël Margueron; Alice Rousseau; Nathalie Droin; Nicolas Cagnard; Sophie Kaltenbach; Susann Winter; Anne-Sophie Kubasch; Didier Bouscary; Valeria Santini; Andrea Toma; Mathilde Hunault; Aspasia Stamatoullas; Emmanuel Gyan; Thomas Cluzeau; Uwe Platzbecker; Lionel Adès; Hervé Puy; Marc-Henri Stern; Zoubida Karim; Patrick Mayeux; Elizabeta Nemeth; Sophie Park; Tomas Ganz; Léon Kautz; Olivier Kosmider; Michaëla Fontenay
Journal:  Sci Transl Med       Date:  2019-07-10       Impact factor: 17.956

3.  RSK2 is a new Pim2 target with pro-survival functions in FLT3-ITD-positive acute myeloid leukemia.

Authors:  M-A Hospital; A Jacquel; F Mazed; E Saland; C Larrue; J Mondesir; R Birsen; A S Green; M Lambert; P Sujobert; E-F Gautier; V Salnot; M Le Gall; J Decroocq; L Poulain; N Jacque; M Fontenay; O Kosmider; C Récher; P Auberger; P Mayeux; D Bouscary; J-E Sarry; J Tamburini
Journal:  Leukemia       Date:  2017-09-15       Impact factor: 11.528

4.  Molecular dissection of engraftment in a xenograft model of myelodysplastic syndromes.

Authors:  Mathieu Meunier; Charles Dussiau; Natacha Mauz; Anne Sophie Alary; Christine Lefebvre; Gautier Szymanski; Mylène Pezet; Françoise Blanquet; Olivier Kosmider; Sophie Park
Journal:  Oncotarget       Date:  2018-02-20

Review 5.  Genetic Hierarchy of Acute Myeloid Leukemia: From Clonal Hematopoiesis to Molecular Residual Disease.

Authors:  Jean-Alain Martignoles; François Delhommeau; Pierre Hirsch
Journal:  Int J Mol Sci       Date:  2018-12-03       Impact factor: 5.923

6.  Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy.

Authors:  Irene Ganan-Gomez; Hui Yang; Feiyang Ma; Guillermo Montalban-Bravo; Natthakan Thongon; Valentina Marchica; Guillaume Richard-Carpentier; Kelly Chien; Ganiraju Manyam; Feng Wang; Ana Alfonso; Shuaitong Chen; Caleb Class; Rashmi Kanagal-Shamanna; Justin P Ingram; Yamini Ogoti; Ashley Rose; Sanam Loghavi; Pamela Lockyer; Benedetta Cambo; Muharrem Muftuoglu; Sarah Schneider; Vera Adema; Michael McLellan; John Garza; Matteo Marchesini; Nicola Giuliani; Matteo Pellegrini; Jing Wang; Jason Walker; Ziyi Li; Koichi Takahashi; Joel D Leverson; Carlos Bueso-Ramos; Michael Andreeff; Karen Clise-Dwyer; Guillermo Garcia-Manero; Simona Colla
Journal:  Nat Med       Date:  2022-03-03       Impact factor: 87.241

7.  Hematopoietic differentiation is characterized by a transient peak of entropy at a single-cell level.

Authors:  Pierre Sujobert; Olivier Gandrillon; Olivier Kosmider; Charles Dussiau; Agathe Boussaroque; Mathilde Gaillard; Clotilde Bravetti; Laila Zaroili; Camille Knosp; Chloé Friedrich; Philippe Asquier; Lise Willems; Laurent Quint; Didier Bouscary; Michaela Fontenay; Thibault Espinasse; Adriana Plesa
Journal:  BMC Biol       Date:  2022-03-09       Impact factor: 7.431

8.  Mapping the CLEC12A expression on myeloid progenitors in normal bone marrow; implications for understanding CLEC12A-related cancer stem cell biology.

Authors:  Marie Bill; Peter B van Kooten Niekerk; Petter S Woll; Laura Laine Herborg; Anne Stidsholt Roug; Peter Hokland; Line Nederby
Journal:  J Cell Mol Med       Date:  2018-02-07       Impact factor: 5.310

9.  Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes.

Authors:  Sophie Park; Olivier Kosmider; Frédéric Maloisel; Bernard Drenou; Nicolas Chapuis; Thibaud Lefebvre; Zoubida Karim; Hervé Puy; Anne Sophie Alary; Sarah Ducamp; Frédérique Verdier; Cécile Bouilloux; Alice Rousseau; Marie-Christine Jacob; Agathe Debliquis; Agnes Charpentier; Emmanuel Gyan; Bruno Anglaret; Cecile Leyronnas; Selim Corm; Borhane Slama; Stephane Cheze; Kamel Laribi; Shanti Amé; Christian Rose; Florence Lachenal; Andrea Toma; Gian Matteo Pica; Martin Carre; Frédéric Garban; Clara Mariette; Jean-Yves Cahn; Mathieu Meunier; Olivier Herault; Pierre Fenaux; Orianne Wagner-Ballon; Valerie Bardet; Francois Dreyfus; Michaela Fontenay
Journal:  Haematologica       Date:  2018-10-04       Impact factor: 9.941

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.